AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32686755 — intervention group
Group type: COMPARATOR
Intervention: Cloth Wrap
Number of subjects: 120
Study 32910710 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 252
Study 32910710 — intervention group
Group type: COMPARATOR
Intervention: 1-year fixed-duration nivolumab
Number of subjects: 252
Study 32910710 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nivolumab
Number of subjects: 252
Study 36503480 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled lung recruitment maneuvers (LRMs) at 12-hour intervals and when clinically indicated
Number of subjects: 30
Study 36503480 — intervention group
Group type: COMPARATOR
Intervention: Only when clinically indicated (control)
Number of subjects: 30
Study 36503480 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled LRMs
Number of subjects: 30
Study 36269184 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated low-level red light (RLRL) therapy
Number of subjects: 62
Study 36269184 — intervention group
Group type: COMPARATOR
Intervention: 0.01% atropine eye drops (LDA)
Number of subjects: 62
Study 32357329 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy and fusion
Number of subjects: 68
Study 32357329 — intervention group
Group type: COMPARATOR
Intervention: Posterior laminectomy with or without fusion
Number of subjects: 68
Study 34969176 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness exercises performed in the classroom over the course of 7 weeks
Number of subjects: 125
Study 32658528 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged control deprivation
Number of subjects: 487
Study 631563192 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean carotid intima-media thickness (cIMT)
Number of subjects: 11547
Study 631563192 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean carotid intima-media thickness (cIMT) categorized in quartiles
Number of subjects: 11547
Study 631563192 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mean arterial pressure (>=109.3 mm Hg)
Number of subjects: 11547
Study 631563192 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher diastolic blood pressure levels (>=90.7 mm Hg)
Number of subjects: 11547
Study 33947856 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ vaccine (1.1 × 10^5 aseptic, purified, cryopreserved PfSPZ of the PfNF54 strain) with 10 mg/kg chloroquine base
Number of subjects: 18
Study 33947856 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline) with 10 mg/kg chloroquine base
Number of subjects: 18
Study 33947856 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ vaccine
Number of subjects: 18
Study 33168081 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed incision negative pressure wound therapy (ciNPWT) for 7 days
Number of subjects: 222
Study 33168081 — intervention group
Group type: COMPARATOR
Intervention: Gauze dressing (control)
Number of subjects: 222
Study 34540636 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural dexmedetomidine
Number of subjects: 45
Study 34540636 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine
Number of subjects: 45
Study 34540636 — intervention group
Group type: COMPARATOR
Intervention: Control (oral medication: cyproterone compound tablets 50 mg BD and diazepam tablets 2 mg TDS for a week)
Number of subjects: 45
Study 35872074 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tacrolimus (5 mg)
Number of subjects: 4874
Study 35872074 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 4874
Study 34491350 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives group
Number of subjects: 344
Study 34491350 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental strategies group
Number of subjects: 344
Study 34491350 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined financial incentives and environmental strategies group
Number of subjects: 344
Study 34491350 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (control)
Number of subjects: 344
Study 35692440 — intervention group
Group type: EXPERIMENTAL
Intervention: CR+SIT LESS (intervention)
Number of subjects: 212
Study 35692440 — intervention group
Group type: COMPARATOR
Intervention: CR (control)
Number of subjects: 212
Study 32768992 — intervention group
Group type: EXPERIMENTAL
Intervention: nabiximols
Number of subjects: 128
Study 32768992 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 128
Study 36137137 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric exercises (PLYO)
Number of subjects: 45
Study 36137137 — intervention group
Group type: EXPERIMENTAL
Intervention: Weightlifting derivatives (WL)
Number of subjects: 45
Study 36137137 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 45
Study 32279141 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese Prostate Cancer Consortium Risk Calculator (CPCC‐RC)
Number of subjects: 617
Study 32279141 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian adapted Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator 3 (A‐ERSPC‐RC3)
Number of subjects: 617
Study 32279141 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision curve analysis for CPCC‐RC
Number of subjects: 617
Study 32279141 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision curve analysis for A‐ERSPC‐RC3
Number of subjects: 617
Study 35279214 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐SOX group (intraperitoneal infusion of docetaxel 30 mg/m2 on d1 and d8, intravenous oxaliplatin 100 mg/m2 on d1, and oral administration of S‐1 on d1‐d14)
Number of subjects: 78
Study 35279214 — intervention group
Group type: COMPARATOR
Intervention: DOS group (intravenous docetaxel 60 mg/m2 on d1, intravenous oxaliplatin 100 mg/m2 on d1, and oral administration of S‐1 on d1‐d14)
Number of subjects: 78
Study 35279214 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐SOX group
Number of subjects: 78
Study 35279214 — intervention group
Group type: COMPARATOR
Intervention: DOS group
Number of subjects: 78
Study 33761207 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg abrocitinib
Number of subjects: 838
Study 33761207 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg abrocitinib
Number of subjects: 838
Study 33761207 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 838
Study 33761207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 838
Study 36134643 — intervention group
Group type: EXPERIMENTAL
Intervention: VLBW/VP group
Number of subjects: 50
Study 36134643 — intervention group
Group type: COMPARATOR
Intervention: ADHD group
Number of subjects: 50
Study 33843647 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized questionnaire assessment of health status
Number of subjects: 355
Study 33843647 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for improving adaptation to a multinational environment
Number of subjects: 355
Study 32024651 — intervention group
Group type: EXPERIMENTAL
Intervention: PGA cut-off of 1.5 cm
Number of subjects: 2600
Study 32024651 — intervention group
Group type: EXPERIMENTAL
Intervention: PGA cut-off of 2.0 cm
Number of subjects: 2600
Study 32024651 — intervention group
Group type: EXPERIMENTAL
Intervention: PGA thresholds (Boolean, 1.5, 2.0, 2.5, 3.0, BooleanX)
Number of subjects: 2600
Study 34425586 — intervention group
Group type: EXPERIMENTAL
Intervention: Cention N (CN)
Number of subjects: 40
Study 34425586 — intervention group
Group type: EXPERIMENTAL
Intervention: Beautifil-bulk Restorative (BB)
Number of subjects: 40
Study 34425586 — intervention group
Group type: EXPERIMENTAL
Intervention: Activa Bioactive Restorative (AV)
Number of subjects: 40
Study 34425586 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Z350 (FZ)
Number of subjects: 40
Study 32247603 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly gemcitabine (1000 mg/m2 on days 1 and 8 of a 21 day cycle) plus pazopanib (800 mg QD)
Number of subjects: 148
Study 32247603 — intervention group
Group type: COMPARATOR
Intervention: Weekly gemcitabine (1000 mg/m2 on days 1 and 8 of a 21 day cycle) alone
Number of subjects: 148
Study 32247603 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly gemcitabine plus pazopanib
Number of subjects: 148
Study 32247603 — intervention group
Group type: COMPARATOR
Intervention: Weekly gemcitabine alone
Number of subjects: 148
Study 36504640 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mechanical thrombectomy (MT)
Number of subjects: 290
Study 36504640 — intervention group
Group type: COMPARATOR
Intervention: Bridging therapy
Number of subjects: 290
Study 33302879 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise intervention + protein placebo + omega-3 fatty acids placebo
Number of subjects: 180
Study 33302879 — intervention group
Group type: EXPERIMENTAL
Intervention: protein + omega-3 fatty acids placebo
Number of subjects: 180
Study 33302879 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise intervention + protein + omega-3 fatty acids placebo
Number of subjects: 180
Study 33302879 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise intervention + protein + omega-3 fatty acids
Number of subjects: 180
Study 33302879 — intervention group
Group type: EXPERIMENTAL
Intervention: protein placebo + omega-3 fatty acids placebo
Number of subjects: 180
Study 35772594 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and laboratory variables (age, pulse, serum urea, serum sodium, white blood cell count)
Number of subjects: 2645
Study 35772594 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic nomogram based on clinical and laboratory variables
Number of subjects: 2645
Study 35772594 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 2645
Study 35772594 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of peritoneal soiling (PS)
Number of subjects: 2645
Study 32005175 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intrajejunal Levodopa Infusion (CLI)
Number of subjects: 66
Study 32005175 — intervention group
Group type: COMPARATOR
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 66
Study 32005175 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CLI and DBS
Number of subjects: 66
Study 35403244 — intervention group
Group type: EXPERIMENTAL
Intervention: SMOF lipid emulsion (SMOF‐LE)
Number of subjects: 528
Study 35403244 — intervention group
Group type: COMPARATOR
Intervention: Non-SMOF lipid emulsion (non–SMOF‐LE)
Number of subjects: 528
Study 32345839 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese (BMI ≥ 30)
Number of subjects: 67
Study 32345839 — intervention group
Group type: COMPARATOR
Intervention: Normal weight (BMI ≤ 25)
Number of subjects: 67
Study 34762731 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut skin diet and SE inoculation (PSSE)
Number of subjects: 160
Study 34762731 — intervention group
Group type: COMPARATOR
Intervention: Control diet with SE inoculation (CONSE)
Number of subjects: 160
Study 34762731 — intervention group
Group type: COMPARATOR
Intervention: Control diet without SE inoculation (CON)
Number of subjects: 160
Study 34762731 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut skin diet without SE inoculation (PS)
Number of subjects: 160
Study 32080823 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg
Number of subjects: 35
Study 32080823 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg
Number of subjects: 35
Study 32080823 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 300 mg
Number of subjects: 35
Study 32080823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 35311317 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategic deception training
Number of subjects: 80
Study 35311317 — intervention group
Group type: COMPARATOR
Intervention: Conservation training control
Number of subjects: 80
Study 34414985 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive stretching
Number of subjects: 3
Study 34414985 — intervention group
Group type: COMPARATOR
Intervention: Handling for active or active-assist movement
Number of subjects: 3
Study 34414985 — intervention group
Group type: COMPARATOR
Intervention: Thermotherapy
Number of subjects: 3
Study 35027405 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 102263
Study 34118188 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan derivatives
Number of subjects: 2
Study 34118188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 33793556 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid immunoglobulin M (IgM)/immunoglobulin G (IgG) test kit
Number of subjects: 844
Study 32289292 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 medications
Number of subjects: 1400
Study 32289292 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 medication
Number of subjects: 1400
Study 32289292 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 medications
Number of subjects: 1400
Study 32289292 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 medications
Number of subjects: 1400
Study 32289292 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 medications
Number of subjects: 1400
Study 36064592 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab every 4 weeks (Q4W)
Number of subjects: 405
Study 36064592 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab at week 0, week 4, then every 8 weeks (Q8W)
Number of subjects: 405
Study 36064592 — intervention group
Group type: COMPARATOR
Intervention: Placebo with crossover to guselkumab at week 24, week 28, then Q8W
Number of subjects: 405
Study 36064592 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab (all dosing regimens)
Number of subjects: 405
Study 32776235 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon catheter (DCB) treatment for ISR
Number of subjects: 396
Study 32776235 — intervention group
Group type: COMPARATOR
Intervention: Plain balloon angioplasty
Number of subjects: 396
Study 32776235 — intervention group
Group type: EXPERIMENTAL
Intervention: DCB treatment for ISR
Number of subjects: 396
Study 34657160 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I) - Healthy Sleep (HS); 4 sessions over 8 weeks
Number of subjects: 175
Study 34657160 — intervention group
Group type: COMPARATOR
Intervention: HF self-management education - Healthy Hearts (HH); attention control
Number of subjects: 175
Study 32521566 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab treatment
Number of subjects: 46
Study 35999068 — intervention group
Group type: EXPERIMENTAL
Intervention: PAD without diabetes
Number of subjects: 48
Study 35999068 — intervention group
Group type: COMPARATOR
Intervention: PAD with diabetes
Number of subjects: 48
Study 35999068 — intervention group
Group type: EXPERIMENTAL
Intervention: PAD with and without diabetes
Number of subjects: 48
Study 34382063 — intervention group
Group type: EXPERIMENTAL
Intervention: High MAP group (average MAP ≥ 70 mmHg)
Number of subjects: 192
Study 34382063 — intervention group
Group type: COMPARATOR
Intervention: Low MAP group (average MAP < 70 mmHg)
Number of subjects: 192
Study 32478913 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood donation
Number of subjects: 36
Study 32478913 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 36235860 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-absorbable geraniol food supplement (LAGS) once daily for four weeks
Number of subjects: 56
Study 36235860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 33710294 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioner-led orthogeriatric care program (NPOCP)
Number of subjects: 300
Study 33710294 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 300
Study 35333199 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid filler Restylane Refyne (HARR, n = 20)
Number of subjects: 26
Study 35333199 — intervention group
Group type: COMPARATOR
Intervention: Saline (n = 6)
Number of subjects: 26
Study 35333199 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle injection
Number of subjects: 26
Study 35333199 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannula injection
Number of subjects: 26
Study 32095992 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaderm
Number of subjects: 151
Study 32095992 — intervention group
Group type: COMPARATOR
Intervention: EyeGard
Number of subjects: 151
Study 35361115 — intervention group
Group type: EXPERIMENTAL
Intervention: Winged and ported catheters (Vasofix® Safety, B. Braun)
Number of subjects: 2304
Study 35361115 — intervention group
Group type: COMPARATOR
Intervention: Non-winged, non-ported catheters (Introcan® Safety, B. Braun)
Number of subjects: 2304
Study 35361115 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle reinsertions during catheterization
Number of subjects: 2304
Study 32734288 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-initiated DMARD self-monitoring service
Number of subjects: 100
Study 32734288 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 32734288 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined costs and effectiveness measures of ESR and quality of life (Short Form-12v1)
Number of subjects: 100
Study 35509708 — intervention group
Group type: EXPERIMENTAL
Intervention: autograft + rhBMP-2
Number of subjects: 30
Study 35509708 — intervention group
Group type: EXPERIMENTAL
Intervention: absorbable collagen sponge + rhBMP-2
Number of subjects: 30
Study 35509708 — intervention group
Group type: EXPERIMENTAL
Intervention: β-tricalcium phosphate + rhBMP-2
Number of subjects: 30
Study 35509708 — intervention group
Group type: EXPERIMENTAL
Intervention: bovine xenograft + rhBMP-2
Number of subjects: 30
Study 35509708 — intervention group
Group type: EXPERIMENTAL
Intervention: hydroxyapatite + rhBMP-2
Number of subjects: 30
Study 35509708 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 30
Study 32427115 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app
Number of subjects: 53
Study 32427115 — intervention group
Group type: COMPARATOR
Intervention: No mobile app
Number of subjects: 53
Study 35609024 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 250mg capsule with ranitidine
Number of subjects: 0
Study 35609024 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 250mg capsule without ranitidine
Number of subjects: 0
Study 32303794 — intervention group
Group type: EXPERIMENTAL
Intervention: High individual lymphocytic subsets and sTIL density
Number of subjects: 1011
Study 32303794 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sTIL density (10% increments)
Number of subjects: 1011
Study 32303794 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher total CD3+ TILs
Number of subjects: 1011
Study 32303794 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher total CD8+ TILs
Number of subjects: 1011
Study 32303794 — intervention group
Group type: EXPERIMENTAL
Intervention: Stromal and intratumoral CD3+, CD8+, and FOXP3+ TIL density
Number of subjects: 1011
Study 35217280 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ascorbic acid (30% in 95% DMSO), applied twice daily for 8 weeks
Number of subjects: 25
Study 35217280 — intervention group
Group type: COMPARATOR
Intervention: Topical imiquimod, a standard topical treatment
Number of subjects: 25
Study 35217280 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ascorbic acid
Number of subjects: 25
Study 35217280 — intervention group
Group type: COMPARATOR
Intervention: Topical imiquimod
Number of subjects: 25
Study 34006020 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 10
Study 34006020 — intervention group
Group type: COMPARATOR
Intervention: Sham transplantation (Control)
Number of subjects: 10
Study 32562721 — intervention group
Group type: EXPERIMENTAL
Intervention: CADe colonoscopy
Number of subjects: 369
Study 32562721 — intervention group
Group type: COMPARATOR
Intervention: Routine colonoscopy
Number of subjects: 369
Study 32562721 — intervention group
Group type: EXPERIMENTAL
Intervention: CADe colonoscopy (ascending colon)
Number of subjects: 369
Study 32562721 — intervention group
Group type: EXPERIMENTAL
Intervention: CADe colonoscopy (transverse colon)
Number of subjects: 369
Study 32562721 — intervention group
Group type: EXPERIMENTAL
Intervention: CADe colonoscopy (descending colon)
Number of subjects: 369
Study 34929354 — intervention group
Group type: EXPERIMENTAL
Intervention: TP-PDT (tri-needle-pretreatment with ALA-PDT)
Number of subjects: 48
Study 34929354 — intervention group
Group type: COMPARATOR
Intervention: NP-PDT (conventional ALA-PDT without pretreatment)
Number of subjects: 48
Study 35835728 — intervention group
Group type: EXPERIMENTAL
Intervention: Goggles and snorkel (GS)
Number of subjects: 40
Study 35835728 — intervention group
Group type: COMPARATOR
Intervention: No goggles and snorkel (NGS)
Number of subjects: 40
Study 33879842 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone + Dronabinol 2.5 mg
Number of subjects: 29
Study 33879842 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone + Dronabinol 5 mg
Number of subjects: 29
Study 33879842 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone + Dronabinol 10 mg
Number of subjects: 29
Study 33879842 — intervention group
Group type: COMPARATOR
Intervention: Hydromorphone only
Number of subjects: 29
Study 33879842 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (2.5 mg, 5.0 mg, 10 mg)
Number of subjects: 29
Study 32973113 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged angioplasty (SAP)
Number of subjects: 64
Study 32973113 — intervention group
Group type: COMPARATOR
Intervention: Regular carotid artery stenting (CAS)
Number of subjects: 64
Study 32027457 — intervention group
Group type: COMPARATOR
Intervention: Fostemsavir 1,200 mg b.i.d.
Number of subjects: 0
Study 32027457 — intervention group
Group type: COMPARATOR
Intervention: Fostemsavir 2,400 mg b.i.d.
Number of subjects: 0
Study 32027457 — intervention group
Group type: EXPERIMENTAL
Intervention: TMR concentrations up to 7,500 ng/mL
Number of subjects: 0
Study 32027457 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir 600 mg b.i.d. (in phase III BRIGHTE study)
Number of subjects: 0
Study 35012798 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
Number of subjects: 0